Home > Media Report > Full Article

IASO Bio to Present at ASH 2019

2019.11.23 | IASO,IASO Bio,IASO Biotherapeutics,IASO Biopharma,CT103A, CAR-T, cell therapy,dual-targeted CAR-T

Nanjing, China., Nov 23, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma' (publication # 582) at American Society of Hematology, 61st ASH Annual Meeting & Exposition in Orlando, FL. on Dec. 7-10.


Detailed information shown below:


Session Name: 653. Myeloma Therapy Excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma


Session Date: Monday, December 9, 2019


Session Time: 7:00 – 8:30 AM


Presentation Time: 8:15 AM


Room: Orange County Convention Center, Hall D


For more information, please visit: